CAR-T Cell Therapy News
City of Hope announced today that it will present data on an abstract titled “Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial” at the American Society of Hematology Annual Meeting Dec. 9 to 12, 2017, at the Georgia World Congress Center in Atlanta.
City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR-T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment.
A research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., chief of neurosurgery, has received a $12.8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund a phase 1 chimeric antigen receptor (CAR)-T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma. The trial will be open to adults and children.
Say the words “brain tumor” and most people will likely think of cancer. But there’s reason for optimism - recent advances in screening and treatment, such as CAR-T cell therapy, mean patient outcomes and quality of life are continuing to improve.
Driven in part by the plight of his patients and his father, chief of neurosurgery Behnam Badie, M.D., spends nearly as much time in the laboratory as he does in the operating room. He wants to help not just today's patients, but tomorrow's.
City of Hope researchers have found that using CAR-T therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma — one of the most aggressive brain tumors known to medicine.
T cells were genetically modified in a lab by City of Hope researchers and trained to target specific receptors on patients’ brain tumors - part of an emerging approach to cancer care called immunotherapy.
Here at ASCO 2017 in Chicago, we’ve been hearing about promising new clinical trials that have shown that immunotherapy can control some of the most resistant cancers.
Studies presented by City of Hope physicians and researchers at the annual meeting of the American Association for Cancer Research (AACR) , could influence future approaches to drug-resistant cancers, treating aggressive brain cancers, recruiting diverse populations for research, and targeted therapies, among other advances.
CAR-T cell therapy research at City of Hope is an innovative and promising approach that recruits the body’s own immune system in the fight against some of the hardest-to-treat cancers, including multiple myeloma.
Dual-trained pediatric oncologist and scientist Leo Wang, M.D., Ph.D., is working in the lab to understand how blood cells develop and grow, and plans to use that information to help patients with cancer live longer and experience fewer side effects of treatment.
City of Hope researchers have seen initial success treating brain cancer patients with CAR-T cell therapy, yet questions still linger about what exactly happens to these cells once they disperse through the brain. A new imaging technique may be the answer.
Sketches of a brain surgery performed on B., one of several patients in a breakthrough clinical trial for brain cancer at City of Hope. Early results of the trial — describing promising results using CAR-T cells for a 50-year-old patient with an aggressive brain cancer called glioblastoma multiforme — were published recently in the New England Journal of Medicine.
City of Hope case study published in the New England Journal of Medicine reported treatment with reengineered CAR-T cells dramatically improved quality of life for patient with recurrent glioblastoma.
One of but a few centers in the United States offering human studies in CAR–T cell therapy, City of Hope is the only center investigating CAR-T cells in injection form administered directly to brain tumors.